How much market share for telaprevir?; Allon gains $10M financing deal; FDA balances regulatory, biomedical sciences;

 @FierceBiotech: Next-gen biotechs pursue 'undruggable' targets. Report | Follow @FierceBiotech

 @JohnCFierce: Had a fine time in Boston talking clinical trials with Sanofi, AstraZeneca, Aveo and Cubist Wednesday. Followed up with finance panel in DC Thursday. | Follow @JohnCFierce

TheStreet's Adam Feuerstein surveyed the news coming from the American Association for the Study of Liver Disease meeting and concluded that the only remaining debate to be had related to the prospects of telaprevir and boceprevir was how much market share each was likely to gain. Feuerstein, a longtime and very enthusiastic fan of telaprevir, estimates that the Vertex drug will come out way ahead. Story

> Canada's Allon Therapeutics has closed a $10 million financing agreement with a wholly owned limited partnership of Nordic Biotech Venture Fund II K/S. Allon release

> Dana-Farber and Novartis have triggered a legal wrangle with Gatekeeper Pharmaceuticals over ownership of an anticancer molecules. Article

> Covance has closed on its ambitious R&D deal with Sanofi-Aventis. Report

And Finally... During the MidAtlantic Bio meeting in Bethesda last week the FDA's Joshua Sharfstein was forced to address some barbed questions from members of the audience upset by the agency's tougher safety standards. He responded that the regulatory sciences have to grow in concert with biomedical research in order to find the right balance between breakthroughs and safety. Item

Suggested Articles

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.